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Abstract
Background
In acute kidney injury (AKI), medication dosing based on Cockcroft-Gault creatinine clear-
ance (CrCl) or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) estimated
glomerular filtration rates (eGFR) are not valid when serum creatinine (SCr) is not in steady
state. The aim of this study was to determine the impact of a kinetic estimating equation that
incorporates fluctuations in SCrs on drug dosing in critically ill patients.
Methods
We used data from participants enrolled in the NIH Acute Respiratory Distress Syndrome
Network Fluid and Catheters Treatment Trial to simulate drug dosing category changes with
the application of the kinetic estimating equation developed by Chen. We evaluated whether
kinetic estimation of renal function would change medication dosing categories (�60, 30–
59, 15–29, and <15mL/min) compared with the use of CrCl or CKD-EPI eGFR.
Results
The use of kinetic CrCl and CKD-EPI eGFR resulted in a large enough change in estimated
renal function to require medication dosing recategorization in 19.3% [95 CI 16.8%–21.9%]
and 23.4% [95% CI 20.7%–26.1%] of participants, respectively. As expected, recategoriza-
tion occurred more frequently in those with AKI. When we examined individual days for
those with AKI, dosing discordance was observed in 8.5% of total days using the CG CrCl
and 10.2% of total days using the CKD-EPI equation compared with the kinetic
counterparts.
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Conclusion
In a critically ill population, use of kinetic estimates of renal function impacted medication
dosing in a substantial proportion of AKI participants. Use of kinetic estimates in clinical
practice should lower the incidence of medication toxicity as well as avoid subtherapeutic
dosing during renal recovery.
Introduction
Acute kidney injury (AKI) is a common occurrence in hospitalized patients [1,2] and has been
associated with increased mortality and longer length of stay [3]. Although newer AKI defini-
tions incorporate urine output, AKI has traditionally been defined based on changes in serum
creatinine (SCr). During AKI, when SCr is fluctuating, standard estimates of creatinine clear-
ance (CrCl) or estimated glomerular filtration rate (eGFR) are not valid, since these equations
assume SCr is at steady state. Furthermore, changes in SCr may lag behind actual changes in
renal function and may take several days to reach steady state during the development of and
recovery from AKI. Thus, estimated CrCl or eGFR may be higher than true GFR while AKI is
developing leading to medication overdosing and lower than true GFR during recovery, lead-
ing to medication underdosing.
Equations [4–8] that incorporate the rate of SCr change have been proposed to estimate
instantaneous GFR during AKI. However, they have not been widely used. In 2013, Chen [9]
developed a simpler algebraic kinetic eGFR (keGFR) equation. In several small cohorts, this
equation has been shown to predict renal-centered outcomes, including delayed graft function,
dialysis-requiring AKI, and renal recovery better than or as well as eGFR or novel biomarkers
[10–15]. As a result of these studies, keGFR is included in the Intensive Care Medicine Agenda
on AKI [16] and Acute Disease Quality Initiative 16 Workgroup [17] as a tool in need of fur-
ther research [18]. However, it is not necessarily surprising that keGFR is superior to standard
estimates of renal function in predicting renal-centered outcomes since by definition, the for-
mer incorporates change in SCr, whereas the latter does not.
Kinetic eGFR may have significant impact for medication dosing during the development
of and recovery from AKI. To date, two studies [19,20] have investigated the use of keGFR in
medication dosing, but neither has quantified the magnitude of changes that would occur if
keGFR was substituted for traditional methods in medication dosing. Dose adjustment based
on renal function has historically used Cockcroft-Gault (CG) CrCl, since this is what has been
recommended by the Food and Drug Administration for drug dosing categories during the
process of drug approval. However, most electronic health records report the Chronic Kidney
Disease-Epidemiology Collaboration (CKD-EPI) eGFR [21] along with SCr. In fact, the FDA
2010 draft guidance has been updated to include eGFR [22] in addition to CrCl to define renal
impairment stages and prepare pharmacokinetic results [23].
We hypothesized that the use of kinetic estimates of renal function could impact drug dos-
ing in a substantial number of critically ill patients with fluctuating renal function. The objec-
tive of the current study. was to examine the frequency with which drug dosing changes would
occur. To test this hypothesis, we conducted a simulation using data from a large, well charac-
terized, critically ill population with the acute respiratory distress syndrome (ARDS), since this
population is known to have a high incidence of AKI [24].
Kinetic GFR estimation in AKI
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Materials and methods
Data source
We used data collected from participants in the Acute Respiratory Distress Syndrome (ARDS)
Network Fluid and Catheter Treatment Trial (FACTT) to quantify medication dosing changes
that would occur with the application of keGFR in a critically ill population [25,26]. This data
is publicly available through the National Heart, Lung and Blood Institute via BioLINCC
(https://biolincc.nhlbi.nih.gov/home/). FACTT was a factorial, randomized clinical trial that
assigned 1000 participants with acute lung injury to either pulmonary artery catheter versus
central venous catheter as well as a fluid liberal versus fluid conservative management strategy.
The trial collected daily SCr closest to 8am and daily maximum values for the first 7 days post
enrollment. We limited the evaluation of kinetic estimates to 8am SCr values. If the 8am SCr
value was missing (9%), the daily maximum SCr value was used. SCr was censored once dialy-
sis was initiated. Participants with at least 2 SCr values remaining after censoring were
included in the study.
AKI definition
AKI was defined by the KDIGO consensus definition as an absolute increase in 0.3mg/dL over
a 48-hour window or a relative increase in serum creatinine of 50% from baseline or need for
dialysis within 7 days of enrollment. Baseline SCr was defined as the value closest to the time
preceding study randomization.
Analysis of renal function and drug dosing categories
Daily renal function was initially determined using the CG CrCl [27] or the CKD-EPI eGFR
[21] equations. The CKD-EPI eGFRs were unadjusted for body surface area using the Mostel-
ler formula- taking the square root of (height in cm �weight in kg/3600) and dividing the value
by 1.73m2 [28,29]. These were compared to kinetic versions of these estimates calculated using
the formula developed by Chen (Fig 1: Equation A) [9]. The maximum change in plasma cre-
atinine was based upon the rate of creatinine generation divided by the volume of distribution
(Fig 1: Equation B). Total body water (TBW), used to determine the volume of distribution,
was defined as 0.6�baseline weight in kilograms (kg).
Equation A:
KeGFR ¼
SSPCr � CrCl
MeanPCr
� 1  
24� DPCr
DTimeðhÞ �MaxDPCr=Day
� �
Equation B:
MaxDPCr ¼
Gen
VolDistrib
¼
SSPCr � CrCl
TBW
We categorized the standard and kinetic estimates of kidney function as recommended by
the FDA Guidance to Industry (> = 60, 30–59, 15–29 or< 15mL/min or mL/min/1.73m2)[23].
The proportion of concordant and discordant category assignments between the standard ver-
sus kinetic measurements were calculated for the participants and for individual study days.
We considered participants to be concordant if the standard and kinetic CrCl or eGFR catego-
ries were the same for all 7 days post-enrollment. Participants were considered discordant if
the standard and kinetic CrCl or eGFR categories were not the same on at least one of those 7
days. For participants with discordant medication dosing categories, the initial change in cate-
gory was used to quantify the impact of the use of kinetic eGFR or CrCl equation. 95%
Kinetic GFR estimation in AKI
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confidence intervals for the percentages of concordance and discordance were calculated
Fig 1. Kinetic eGFR equation as formulated by Chen et al. (Equation A) SSPCr denotes steady state plasma creatinine (in this analysis, serum creatinine at
enrollment. CrCl is the estimated glomerular filtration rate calculated using the Cockcroft-Gault or CKD-EPI (unadjusted for body surface area) estimating
equation with the SSPCr. Mean PCr is the mean of SCr from that day and SCr from 24 hours prior. ΔPCr denotes the difference between the SCr from that
day and SCr from 24 hours prior. Max ΔPCr indicates maximum change in creatinine per day as estimated by equation B. (Equation B) Max ΔPCr is
calculated from the rate of creatinine generation divided by the volume of distribution. The total body water was defined as 0.6�baseline weight in kilograms.
https://doi.org/10.1371/journal.pone.0225601.g001
Table 1. Baseline characteristics of all FACTT subjects included in the analysis of kinetic GFR, and then divided by the presence and absence of AKI.
ALL subjects No AKI AKI P value
Number of subjects, n 946 450 496
Demographics
Age (years) 50 ± 16 49 ± 16 50 ± 16 0.30
Female, n (%) 437 (46%) 216 (48%) 221 (45%) 0.29
African American, n (%) 200 (21%) 76 (17%) 124 (25%) < 0.01
Weight (kg) 81 ± 23 80 ± 22 82 ± 24 0.32
Fluid Liberal Arm, n (%) 470 (50%) 246 (54%) 228 (45%) <0.01
Comorbidities
Diabetes, n (%) 162 (18%) 62 (14%) 100 (21%) 0.02
HTN, n (%) 226 (29%) 90 (24%) 136 (34%) <0.01
Renal Function at Time of Study Enrollment
Creatinine (mg/dL) 1.0 [0.7–1.5] 0.9 [0.7–1.2] 1.2 [0.8–1.7] < 0.01
CG CrCl, ml/min 92 [58, 134] 104 [68–140] 81 [50–126] < 0.01
CKD-EPI eGFR, ml/min/1.73m2 90 [55–119] 100 [69–123] 79 [47–115] < 0.01
Severity of Illness
On vasopressors at time of enrollment, n (%) 396 (42%) 173 (38%) 223 (45%) 0.04
APACHE III Score 92 ± 30 86± 28 98 ± 30 < 0.01
Outcomes
Ventilator Free Days 18 [0–23] 21 [10–25] 10 [0–22] < 0.01
Dialyzed within 60 days, n (%) 91 (10%) 4 (1%) 87 (18%) < 0.01
Mortality within 60 days, n (%) 240 (25%) 70 (16%) 170 (34%) < 0.01
Data is displayed as mean ± SD, median [IQR] and n (%).
https://doi.org/10.1371/journal.pone.0225601.t001
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using binomial distributions. A sensitivity analysis was also conducted where those whose esti-
mates (standard versus kinetic) were less than 5mL/min or 5mL/min/1.73m2 apart were
counted among the proportion of those who did not require reclassification.
Fluid adjusted analyses
Because the FACTT trial included a fluid management strategy, and fluid overload may affect
ascertainment of serum creatinine and AKI [24], a secondary analysis was completed using
fluid-adjusted creatinine using the method described by Macedo et al [30]. For each study day,
the cumulative on-study fluid balance was calculated using the 24 hour fluid intake and output
where Adjust Cr = SCr �[1+ on study cumulative net fluid balance/TBW]. We examined the
proportion of subjects requiring drug dosing reclassification in 4 groups: those who did not
have AKI before or after adjustment for fluid balance, those with AKI only after adjustment
for fluid balance, those who had AKI before but not after adjustment for fluid balance, and
those with AKI both before and after adjustment for fluid balance, as previously described.
Statistical analyses
Differences in means were compared using analysis of variance (ANOVA) while rank differ-
ences were compared using the Kruskal-Wallis test. Differences in proportions were con-
ducted using Pearson’s chi squared test. Data analysis was conducted using Stata 15.1
(StataCorp, College Station, TX). P values< 0.05 were considered statistically significant.
Results
A total of 54 FACTT participants were excluded as a result of dialysis requirement or death
within day 1 of recruitment [N = 28] or missing data that did not allow for kinetic estimates
[N = 26]. The final population was composed of 946 participants, with baseline characteristics
as shown in Table 1. 496 (52%) developed AKI within 7 days of enrollment. An additional 110
participants developed AKI later in the study but were not considered to have AKI for this
analysis. Age, sex, and weight were similar among those with and without AKI. However,
there were notably more African Americans who had AKI. Patients who developed AKI were
also more likely to have diabetes, hypertension, and have higher creatinine at baseline. At the
time of recruitment, they were also more likely to have greater severity of illness, with higher
rates of vasopressor use and higher acute physiology and chronic health evaluation III
(APACHE III) scores. In the primary analysis (where there was no adjustment for differences
in fluid balance between the treatment arms), participants with AKI were less likely than those
without AKI to be have been randomized to the fluid liberal arm (45 vs 54%, p<0.01), similar
to prior work [24,31]. Those with AKI had fewer ventilator free days (median 10 vs 21,
p< 0.01) and higher 60-day mortality (16% vs 34%, p< 0.01).
We next compared drug dosing CrCl or eGFR categories (�60, 30–59, 15–29, and<15mL/
min) using standard and kinetic estimates. Fig 2 illustrates CrCl over time in a subject who
had worsening AKI followed by renal recovery. In this subject, kinetic estimates were lower
than the CrCl in the setting of AKI and worsening renal function, whereas the kinetic esti-
mates were higher than the CrCl during recovery.
When kinetic estimates were compared to standard estimates, 19.3% [95% CI 16.8%–
21.9%] of participants and 23.4% [95% CI 20.7%–26.1%] required any change in dosing cate-
gory on at least one study day using the CG CrCl and unadjusted for BSA CKD-EPI equations,
respectively (Table 2). Those with AKI were more likely to have discordant standard and
kinetic dosing categories. For example, when CG CrCl was used, 33.5% [95% CI 29.3%–
37.6%] of those with AKI versus 3.8% [95% CI 2.0%-5.5%] of those without AKI required any
Kinetic GFR estimation in AKI
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change in dosing category using the kinetic estimate. Those who were not classified as having
Fig 2. Sample application of kinetic estimate. Panel A illustrates the creatinine trajectory of one participant with AKI within
the first 7 study days; Panel B illustrates the corresponding calculated CG CrCl and CKD-EPI eGFRs and their corresponding
kinetic estimates. Horizontal lines in the figure demarcate FDA dosing categories (e.g., 15, 30, and 60mL/min). After the rapid
creatinine rise during the development of severe AKI, the kinetic CG CrCl fell to within the 15–30mL/min dosing category on
Day 1, while the CG CrCl dosing category was 30–60mL/min. This subject would be considered to have discordant drug dosing
categories on this day. Conversely, on Day 7, the kinetic estimate is higher than the CG CrCl because of the lag in SCr decline
during renal recovery. Using the CKD-EPI equation, discordant drug dosing categories only occurred on Day 1. On other study
days, drug dosing categories were concordant.
https://doi.org/10.1371/journal.pone.0225601.g002
Kinetic GFR estimation in AKI
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AKI mostly required dosing adjustment during falls in serum Cr which likely represent recov-
ery from AKI. In a sensitivity analysis, we removed small changes (< 5mL/min between
kinetic and nonkinetic estimates) from the recategorization analysis. For example, in the sensi-
tivity analysis, if the CrCl was 32mL/min and the kinetic CrCl was 28mL/min, the participant
was not considered to have a change in medication dosing category for that day. There was a
smaller proportion of individuals with discordant dosing categories (13.6% for CG Cl, [95% CI
11.4%-15.8%]; 16.0% [95% CI 13.7–18.4%] for CKD-EPI eGFR, S1 Table) but the proportion
was still substantial.
For a given participant, the use of kinetic estimates may only affect drug dosing practices
on a subset of study days. As illustrated by data from a study participant with AKI in Fig 2,
kinetic estimates would have changed daily dosing practices on 3 of 7 study days (Day 1, 3, and
7). When we examined individual days for the entire study population (Table 3), dosing dis-
cordance was observed in 4.6% of total days using the CG CrCl and 6.0% of total days using
the CKD-EPI equation (S2 Table). Irrespective of AKI status, concordance between CG CrCl
and kinetic GFR estimated drug categories decreased with lower GFR. In those with AKI, the
drug dosing discordance increased to 8.5% of total days using the CG CrCl equation and
10.2% of total days using the CKD-EPI equation. Discordance occurred during both the estab-
lishment of AKI and recovery. The discrepancy occurred most frequently immediately post
study enrollment and declined over time (S3 Table). The decline in discordance over time was
more prominent when the CG CrCl was applied compared to the CKD-EPI equation.
As a final sensitivity analysis, because the FACTT trial involved a specific fluid management
strategy, the analysis was repeated using fluid corrected SCr as described in Macedo et al (S4
Table) [30]. 3 subjects were excluded because they had only 1 day of fluid data. With fluid cor-
rection, the proportion of subjects requiring drug dosing recategorization increased overall
(from 19.4% to 23.4% using the CG CrCl equation and from 23.4% to 25.2% using the
CKD-EPI equation). Recategorization occurred least in those who did not meet the AKI defi-
nition using either non-fluid corrected or fluid corrected creatinine values (3.2% using the CG
CrCl equation and 3.9% using the CKD-EPI equation) and most in those who met AKI
Table 2. Dosing recategorization using kinetic estimates of CrCl and eGFR. The percentage of patients who
required recategorization with use of kinetic estimates of each formula is shown, stratified by AKI status. The number
of drug dosing categories crossed (>60, 30–60, 15–29,< 15ml/min) refers to the initial study day that redosing was
required.
ALL (n = 946) No change % (n)
[95% CI]
±1 category % (n)
[95% CI]
±2 categories % (n)
[95% CI]
Cockcroft-Gault CrCl 80.7% (763)
[78.1%, 83.1%]
18.3% (173)
[15.8%, 20.8%]
1.0% (10)
[0.4%-1.7%]
CKD-EPI 76.6% (725)
[73.9%-79.3%]
22.6% (214)
[20.0%, 25.3%]
0.7% (7)
[0.1%-1.3%]
No AKI (n = 450) No change ±1 category ±2 categories
Cockcroft-Gault CrCl 96.2% (433)
[94.5%-98.0%]
3.8% (17)
[2.0%-5.5%]
0% (0)
—
CKD-EPI 92.7% (417)
[90.3%-95.1%]
7.3% (33)
[4.9%-9.7%]
0% (0)
—
AKI (n = 496) No change ±1 category ±2 categories
Cockcroft-Gault CrCl 66.5% (330)
[62.4–70.7%]
31.5% (156)
[27.3%-35.5%]
2.0% (10)
[0.8%-3.3%]
CKD-EPI 62.1% (308)
[57.8%-66.4%]
36.5% (181)
[32.3%-40.7%]
1.4% (7)
[0.3%-2.4%]
https://doi.org/10.1371/journal.pone.0225601.t002
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definitions using both non-fluid corrected and fluid corrected group (44.0% using the CG
CrCl equation and 44.2% using the CKD-EPI equation).
Discussion
At present, there is no standardized way to dose medications in AKI given fluctuating kidney
function and filtration markers such as SCr. This is problematic during the development of
AKI, when CrCl or eGFR will overestimate renal function and may lead to drug accumulation
and potential toxicity as well as during renal recovery, when CrCl or eGFR will underestimate
renal function and therapeutic drug levels may not be attained. There has been interest in the
use of kinetic equations to refine estimates of renal function. Here, we show in a critically ill
population of patients with ARDS that the use of the Chen kinetic estimating equation might
affect drug dosing in a quarter of critically ill patients. Amongst those with AKI, drug dosing
would be impacted in 33.5% and 37.9% of patients using the CrCl equation and CKD-EPI
equation, respectively.
Furthermore, we found that the kinetic equation impacts drug dosing the most at lower
eGFRs. This may be because at lower estimates of renal function, a 50mL/min adjustment (e.g.
from 60 to 10mL/min) by the kinetic equation results in a change of two dosing categories. In
contrast, at higher levels of renal function, similar adjustments (e.g. from 120 to 70mL/min)
would not require any drug redosing. The impact of kinetic equations is also most prominent
in the first few days of hospitalization and wanes over time, especially when kinetic CrCl is
applied rather than the kinetic CKD-EPI equation. We suspect that the differential impact of
the two equations over time is secondary to lower serum creatinine values observed during
renal recovery later in the hospitalization. Traditionally, the CG CrCl equation results in
Table 3. Dosing recategorization by study days. Comparison of dosing categories for all study days using the kinetic versus standard Cockcroft Gault CrCl in all subjects
and then divided by AKI status. Subjects along the diagonal have concordant drug dosing using the two estimates, whereas those in the off-diagonal cells have discordant
drug dosing using the two estimates. The majority of drug redosing occurs in subjects who experienced AKI.
ALL Subjects Kinetic CG CrCl Categories (4.6% Recategorized)
CG CrCl Categories > = 60mL/min 30–59 mL/min 15–29mL/min < 15mL/min Total
> = 60 mL/min 4481 39 0 0 4520
30–59 mL/min 28 848 77 10 963
15–29 mL/min 0 30 222 82 334
< 15 mL/min 0 0 4 49 53
Total 4509 917 303 141 5870 days
No AKI Kinetic CG CrCl Categories (0.6% Recategorized)
CG CrCl Categories > = 60mL/min 30–59 mL/min 15–29mL/min < 15mL/min Total
> = 60 mL/min 2597 2 0 0 2599
30–59 mL/min 10 272 1 0 283
15–29 mL/min 0 4 24 0 28
< 15 mL/min 0 0 0 1 1
Total 2607 278 25 1 2911 days
AKI Kinetic CG CrCl Categories (8.5% Recategorized)
CG CrCl Categories > = 60mL/min 30–59 mL/min 15–29mL/min < 15mL/min Total
> = 60 mL/min 1884 37 0 0 1921
30–59 mL/min 18 576 76 10 680
15–29 mL/min 0 26 198 82 306
< 15 mL/min 0 0 4 48 52
Total 1902 639 278 140 2959 days
https://doi.org/10.1371/journal.pone.0225601.t003
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higher estimates of renal function compared to the CKD-EPI equation at low values of serum
creatinine, and, as described above, at higher levels of estimated renal function, kinetic adjust-
ments are less likely to result in changes in drug dosing categories.
Over the last few years, Chen’s kinetic equation has been increasingly used and validated in
various settings. In the intensive care setting, keGFR performed better than several novel bio-
markers in predicting renal recovery and major adverse kidney events [11]. KeGFR has been
also tested in patients undergoing cardiac surgery for predicting AKI and operative mortality
[14]. The equation has also been implemented in the renal transplant population to improve
early AKI detection in living donors [32], to predict delayed graft function in renal transplant
recipients [10,13] and as a secondary endpoint for a randomized clinical trial where those ran-
domized to balanced salt solutions (Plasma-lyte) versus normal saline trended towards better
keGFR [33]. Together, these studies show that keGFR improves prediction and understanding
of renal function in AKI when the serum creatinine is rapidly fluctuating. However, there are
limited studies evaluating keGFR for the purposes of drug dosing[19,20]. Harada [19] et al.
compared measured vancomycin concentrations with predicted vancomycin concentrations
derived using varying estimates of renal function, but the predicted concentration [34] was
derived from CG CrCl, which will bias the results in favor of the CG equation. Pharmacist-led
medication dosing tends to use CG CrCl because the previous US Food and Drug Administra-
tion guidance on pharmacokinetic categories is based on CrCl. In contrast, nephrologists typi-
cally use eGFR estimates for medication dosing in CKD, which may lead to discrepant dosing
recommendations [35,36].
In AKI, steady state estimating equations perform poorly. In a study conducted by Braga-
dottir et al. [37], the within group-error was 68.7%, 67.7% and 68.0% for MDRD eGFR,
CKD-EPI eGFR and CG CrCl respectively when compared to the measured GFR (measured
by 51Cr-EDTA) in early AKI. Equations that account for SCr kinetics may improve the evalua-
tion of renal function in AKI. The Jelliffe formula, one of the first kinetic GFR equations, has
been shown to be superior to estimating equations in small prior studies [6,38]. In AKI, eGFR
by the CG CrCl, MDRD eGFR and Jelliffe formulas overestimated urinary creatinine clearance
80%, 33% and 10% of the time respectively [38]. Although the Chen formula was not tested,
these results imply that kinetic approaches may improve the evaluation of kidney function in
AKI. Compared to earlier formulas, the Chen formula provides algebraic simplicity that allows
for easier implementation into clinical practice.
Our study sought to determine the impact of keGFR on drug dosing if keGFR was widely
applied into the electronic health record, eliminating the need for labor intensive timed urine
clearance measurements. Although therapeutic drug level monitoring can be used for certain
medications (e.g., vancomycin), there are relatively few medications where real-time monitor-
ing is feasible. Commonly used, important medications in critically ill patients often require
redosing based on GFR category. For example, the therapeutic dose range for cefepime varies
from 2 g every 8 hours in the setting of normal renal function to 1 g intravenous every 24
hours in the setting of GFR < 10 mL/min for pseudomonal infections. Cefepime accumulation
can lead to encephalopathy and coma, yet underdosing can lead to inadequate treatment of
infections. Incorporation of keGFR into the electronic health record may help critical care pro-
viders easily adjust cefepime dosing daily to avoid toxicity in the setting of worsening AKI
and, just as importantly, avoid underdosing during renal recovery. Future approaches may
also include the use of novel filtration biomarkers such as cystatin C and real time GFR mea-
surement, which are likely to be soon available to evaluate drug clearance in AKI. However, it
is unlikely that real time GFR measurement will be implementable in all patients across all set-
tings. Therefore, further studies are necessary to compare keGFR with measured GFR to allow
for a cost-effective and efficient way for estimating GFR in AKI.
Kinetic GFR estimation in AKI
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The strengths of this study include the use of a diverse, large critically ill population with
daily creatinine data. We selected drug dosing categories that are large and clinically meaning-
ful. Therefore, the results should be relatively robust to small changes in eGFR. Furthermore,
there is limited missing data. In cases where patients were excluded due to kinetic estimates
not available secondary to death/early dialysis, it is presumed that if kinetic GFR was applied at
later dates, the proportion of participants who need dosing adjustment with application of
keGFR would increase. Thus, this study provides a relatively conservative estimate of those
who would be affected.
This study has some limitations. First, while we quantified the proportion of participants
and days that required a change in medication dosing, we did not have drug toxicity or levels
available; in fact, drug levels are rarely available to guide dosing. As such, we cannot identify
whether redosing medications using these kinetic formulas would directly impact participant
outcomes. Higher mortality was observed in those who would have required medication
redosing, but this is likely due to the severity of illness associated with AKI rather than medica-
tion toxicity or subtherapeutic medications.
Conclusions
In this large critically ill population with ARDS and an overall AKI rate of 52%, the use of
kinetic estimates of renal function would likely impact drug dosing in a quarter of all subjects
during the first week of admission. Most of this drug redosing would occur in participants
with AKI, and in this analysis, approximately 8–10% of study days among those with AKI
would be impacted. Thus, the magnitude of drug redosing that might occur in critically ill
patients with the use of keGFR warrants additional studies to further test the clinical utility of
keGFR.
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